Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

We have observed 5 EP applications Mylène Audrey Séverine Quellari has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after May 28, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11749535

ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

IPC classification:
A61P 35/00, C07D 487/04
Applicant:
Sanofi, S.A.
Agent:
Mylène Audrey Séverine Quellari, Sanofi, S.A.
Status:
GRANT OF PATENT INTENDED
EP12806060

NOVEL THERAPEUTIC USE OF P75 RECEPTOR ANTAGONISTS

IPC classification:
A61K 31/497, A61K 31/498, A61K 31/506, A61P 13/10
Applicant:
Sanofi, S.A.
Agent:
Mylène Audrey Séverine Quellari, Sanofi, S.A.
Status:
EXAMINATION IN PROGRESS
EP11796752

NOVEL INDOLIZINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF

IPC classification:
A61K 31/443, A61P 9/00, C07D 471/04
Applicant:
Sanofi, S.A.
Agent:
Mylène Audrey Séverine Quellari, Sanofi, S.A.
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14784452

4-[5-(3-CHLORO-PHENOXY)-OXAZOLO[5,4-D]PYRIMIDIN-2-YL]-2,6-DIMETHYL-PHENOXY}-ACETIC ACID FOR USE IN THE PREVENTION OR TREATMENT OF ACUTE KIDNEY INJURY

IPC classification:
A61K 31/519, A61P 13/12
Applicant:
Sanofi, S.A.
Agent:
Mylène Audrey Séverine Quellari, Sanofi, S.A.
Status:
GRANT OF PATENT INTENDED
EP16721844

CABAZITAXEL AND ITS USE FOR TREATING CANCER

IPC classification:
A61K 31/337, A61P 35/00
Applicant:
Aventis Pharma S.A.
Agent:
Mylène Audrey Séverine Quellari, Sanofi, S.A.
Status:
Request for examination was made

Please Sign in to use this feature